Viatris Launches $36.50 Tender for Pacira BioSciences, Clock Now Running

Viatris commenced its tender offer for all outstanding shares of Pacira BioSciences at $36.50 cash per share on Thursday, moving the $2.9 billion transaction from announcement to execution. Peach Purchaser Sub, a wholly owned subsidiary of Viatris, filed the formal Schedule TO with the SEC, triggering the standard 20-business-day minimum tender window. The offer price represents a 32% premium to Pacira's 30-day volume-weighted average price prior to deal rumors surfacing in late March.

Pacira closed at $35.82 on Wednesday, a 1.9% discount to the tender price—a spread that suggests the market assigns minimal regulatory or financing risk to the combination. The company's sole commercial asset, Exparel, a long-acting local anesthetic, generated $548 million in revenue over the trailing twelve months. Viatris is acquiring both the product and a late-stage pipeline candidate, zilretta, a corticosteroid injection for osteoarthritis pain that entered Phase III trials in Q4 2024. The deal consolidates two overlapping go-to-market infrastructures in hospital-based pain management, a category where formulary access and GPO relationships drive volume more than brand preference.

This matters because Viatris is buying duration in a shrinking universe of non-opioid pain assets at a time when hospital systems face intensifying scrutiny over opioid stewardship protocols. Exparel's patent exclusivity runs through 2031 in the United States, with pediatric exclusivity adding six months. The acquisition effectively doubles Viatris's exposure to the ambulatory surgery center channel, which has grown at a 6.4% CAGR since 2019 as Medicare Advantage plans push lower-acuity procedures out of inpatient settings. The $36.50 price implies Viatris is paying roughly 5.3x trailing revenue—a modest multiple for a product with line-of-sight to $650 million in annual sales by 2027, assuming current procedural volume trends hold. The integration risk centers on whether Viatris can extract $150 million in annual synergies, the figure management cited in the initial announcement, without triggering formulary disruptions during the rebate renegotiation cycle that begins in Q1 2026.

Allocators should watch three events over the next 90 days. First, the HSR waiting period expires May 19, barring a second request from the FTC—unlikely given the fragmented nature of the anesthesia market and the absence of overlapping molecules. Second, Pacira's Q1 earnings on May 8 will show whether Exparel volume held steady during the uncertainty period; any sequential decline above 3% would raise questions about sales force attrition. Third, Viatris's May 21 refinancing of its $1.8 billion term loan B will clarify the cost of capital embedded in this transaction. The company has $3.2 billion in cash and marketable securities, enough to fund the deal without tapping the revolver, but the pricing on the new term loan will signal how credit markets view Viatris's post-deal leverage profile.

The tender closes June 5 unless extended. By June 12, Viatris will either own a durable hospital franchise or will have taught the market that non-opioid pain assets command higher multiples than the generic playbook allows.